Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

September 27, 2022

https://www.globenewswire.com/news-release/2022/09/27/2523218/0/en/Cognition-Therapeutics-Awarded-2-14-Million-in-Supplemental-Grant-Funding-from-NIA-to-Support-SEQUEL-Clinical-Trial.html

PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) —  Cognition Therapeutics, Inc. (Nasdaq:CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease. The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).

Read more at globenewswire.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.